医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

JA Mitsui Leasing Acquires Katsumi Global, LLC.

2023年07月14日 AM01:19
このエントリーをはてなブックマークに追加


 

TOKYO

JA Mitsui Leasing Ltd. (headquarter: Chuo-ku, Tokyo; Keito Shimbu, President and CEO; hereinafter referred to as “JAML”) announces, that through our subsidiary, JA Mitsui Leasing Capital Corporation (headquarter: NY, USA; Kiyoshi Doi, Director, President; hereinafter referred to as “JMCC”), we have acquired 100% interest in Katsumi Global, LLC (headquarter: Michigan, USA; Tim King, CEO; hereinafter referred to as “KG”).

1. Background and Purpose of the Investment

JAML is expanding our business in North America in line with our Mid-term Management Plan, namely “Real Change 2025.” JMCC will leverage KG’s platform, experience with working capital solutions such as supply chain financing, and people in combination with JAML’s financial strength and customer network to expand the services provided to customers in North America.

2. Overview of Katsumi Global, LLC

Company Name

Katsumi Global, LLC

Headquarter

Michigan, USA

Established

July 2020

CEO

Tim King

Business

Provides global working capital strategies and solutions to mid/large corporations.

About JA Mitsui Leasing, Ltd.

JAML is a Japanese leasing company providing leasing and financial solution in Japan and Globally (offices in Asia and North America), with total operating assets over USD 16 billion. The main shareholders are The Norinchukin Bank and Mitsui & Co., Ltd., both A rated by S&P. By combing the features of both parent companies, JAML takes advantage of its multiple channels, leading financial parents and ample client network to provide Asset Finance solutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230713364720/en/

CONTACT

PR & IR Department, Corporate Management Division, JA Mitsui Leasing, Ltd.

Phone: +81-3-6775-3002, E-Mail:JAMLDG1114@jamitsuilease.co.jp

同じカテゴリーの記事 

  • Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
  • Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris
  • Southeast Asian Countries Lead in Positive Experiences
  • Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
  • Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver